var data={"title":"Diclofenac (topical): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diclofenac (topical): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/388156?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=diclofenac-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Diclofenac (topical): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016814\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious cardiovascular thrombotic events (Flector, Klofensaid II, Pennsaid, Solaraze, and Voltaren):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious gastrointestinal bleeding, ulceration and perforation (Flector, Klofensaid II, Pennsaid, and Voltaren):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse reactions, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These reactions can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk of serious GI events.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016848\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Diclo Gel;</li>\n      <li>Diclo Gel with Xrylix Sheets;</li>\n      <li>Diclozor;</li>\n      <li>DSG Pak [DSC];</li>\n      <li>DST Plus Pak;</li>\n      <li>EnovaRX-Diclofenac Sodium;</li>\n      <li>Flector;</li>\n      <li>Klofensaid II;</li>\n      <li>Lexixryl;</li>\n      <li>Pennsaid;</li>\n      <li>Rexaphenac;</li>\n      <li>Solaraze [DSC];</li>\n      <li>Voltaren;</li>\n      <li>Vopac MDS;</li>\n      <li>Xrylix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016849\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pennsaid;</li>\n      <li>Voltaren Emulgel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017363\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Nonsteroidal Anti-inflammatory Drug (NSAID);</li>\n      <li>\n        Nonsteroidal Anti-inflammatory Drug (NSAID), Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017006\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Use the lowest effective dose for the shortest duration of time, consistent with individual patient treatment goals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Actinic keratosis (AK):</b> Topical: Apply 3% gel to lesion area twice daily for 60 to 90 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute pain (strains, sprains, contusions):</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patch: Apply 1 patch twice daily to most painful area</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gel (Voltaren Emulgel [Canadian products]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1.16%: Apply 2 g to 4 g to the skin over affected area(s) 3 or 4 times daily for up to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2.32%: Apply 2 g to the skin over affected area(s) twice daily for up to 7 days (maximum: 4 g/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoarthritis:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gel: <b>Note:</b> Maximum total body dose of 1% gel should not exceed 32 g per day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lower extremities: Apply 4 g of 1% gel to affected area 4 times daily (maximum: 16 g per joint per day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Upper extremities: Apply 2 g of 1% gel to affected area 4 times daily (maximum: 8 g per joint per day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution: Knee:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1.5% solution: Apply 40 drops to each affected knee 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2% solution: Apply 2 pump actuations to each affected knee twice daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13713274\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute pain (strains, sprains, contusions):</b> Topical: Gel (Voltaren Emulgel 1.16% [Canadian product]): Adolescents &ge;16 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017029\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Start at lower end of dosing range. Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24789061\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; avoid use in patients with advanced renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24789062\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017238\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, Transdermal, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EnovaRX-Diclofenac Sodium: 2.5% (60 g) [contains cetyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rexaphenac: 1% (120 g) [contains isopropyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Transdermal, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solaraze: 3% (100 g [DSC]) [contains benzyl alcohol, polyethylene glycol, sodium hyaluronate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Voltaren: 1% (100 g) [contains isopropyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1% (100 g); 3% (100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Transdermal, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diclo Gel: 1% [contains isopropyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DST Plus Pak: 1% [contains isopropyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vopac MDS: 1.5% [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch, Transdermal, as epolamine: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flector: 1.3% (5 ea, 30 ea) [contains edetate disodium, methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Transdermal, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klofensaid II: 1.5% (150 mL) [contains alcohol, usp, dimethyl sulfoxide, glycerin, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pennsaid: 1.5% (150 mL [DSC]); 2% (2 g, 112 g) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.5% (150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Therapy Pack, External, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diclo Gel with Xrylix Sheets: 1% (1 ea) [contains isopropyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Therapy Pack, Transdermal, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diclozor: 1% (1 ea) [contains isopropyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DSG Pak: 1% (1 ea [DSC]) [contains isopropyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lexixryl: 1.5% (1 ea) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xrylix: 1.5% (1 ea) [contains propylene glycol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016851\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27368393\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclozor therapy pack contains diclofenac gel (2 x 100 g) and occlusive dressings (10s).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DSG Pak contains Voltaren gel (100 g) and occlusive dressings (20s).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DST Plus Pak kit contains diclofenac gel.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EnovaRX-Diclofenac Sodium is a compounding kit for the preparation of diclofenac cream. Refer to manufacturer's labeling for compounding instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lexixryl therapy pack contains diclofenac solution (150 mL) and Xrylix kinesiology/cross tape (30s).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rexaphenac is a compounding kit for the preparation of diclofenac cream. Refer to manufacturer's labeling for compounding instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xrylix therapy pack contains diclofenac solution (150 mL) and Xrylix kinesiology/cross tape (30s).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vopac MDS kit contains diclofenac solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9550525\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, topical, as diethylamine:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Voltaren Emulgel: 1.16% (20 g, 50 g, 100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Voltaren Emulgel Extra-Strength: 2.32% (30 g, 100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, topical, as sodium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pennsaid: 1.5% (15 ml, 30 mL, 60 mL, 120 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016847\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Flector: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088598.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlCQzXXMwlH8WSSTKmHP2HDg==&amp;TOPIC_ID=9108\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088598.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">NSAID: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WJqYrx1xLSb8GxuJFaqJ8Kg==&amp;TOPIC_ID=9108\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Pennsaid: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM191085.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQBoCrSHwHS9IlCXQ2qRiigg==&amp;TOPIC_ID=9108\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM191085.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Solaraze: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM501655.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn//CovC0x0ey2BbNY46aAsKL5/4JoYFvYZrn5/TyfOfv0w==&amp;TOPIC_ID=9108\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM501655.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Voltaren: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlXy07xMqYjc5Z/G5Gnd69Bw==&amp;TOPIC_ID=9108\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017033\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel: Do not apply to open wounds, eyes, or mucous membranes. Do not cover with occlusive dressings or apply heat, sunscreens, cosmetics, lotions, moisturizers, insect repellents, or other topical medications to affected area. Showering/bathing should be avoided for at least 1 hour following application. Wash hands immediately after application (unless hands are treated joint, then wait at least 1 hour to wash hands). Avoid sunlight to exposure areas. Avoid wearing clothes or gloves for &ge;10 minutes after application.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% formulation: Use dosing card to measure dose. Apply to affected area or joint and rub into skin gently, making sure to apply to entire affected area or joint.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3% formulation: Apply to lesion and smooth into skin gently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Voltaren Emulgel [Canadian products]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1.16% formulation: Apply to affected area and rub gently into skin; 1 g equals a strip ~2 cm long</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2.32% formulation: Use dosing card to measure dose. Apply to affected area or joint and rub into skin gently, making sure to apply to entire affected area or joint.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution: Apply to clean, dry, intact skin; do not apply to eyes, mucous membranes, or open wounds. Wash hands before and after use. Do not shower or bathe for at least 30 minutes after applying. Allow knee to dry before applying clothing. Do not apply heat or occlusive dressing to treated knee; protect treated knee from sunlight. Cosmetics, insect repellant, lotion, moisturizer, sunscreens, or other topical medication may be applied to treated knee once solution has dried.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1.5% formulation: Apply 10 drops at a time either directly onto knee <b>or</b> into hand then onto knee (helps avoid spillage). Spread evenly around knee (front, back, sides). Repeat procedure until total dose applied and the knee is completely covered with solution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">2% formulation: The pump must be primed before first use. To prime, fully depress the pump 4 times while holding the bottle in an upright position. This portion should be discarded to ensure proper priming of the pump. No further priming of the bottle is required. Press the pump 2 times to deliver the solution onto the palm of the hand, and apply evenly around the front, back, and sides of the affected knee.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch: Apply to intact, nondamaged skin. Remove transparent liner prior to applying to skin. Wash hands after applying, handling, or removing the patch. May tape down edges of patch, if peeling occurs; if problems with adhesion persist, may overlay the patch with a mesh netting sleeve. Should not be worn while bathing or showering. Fold used patches so the adhesive side sticks to itself; dispose of used patches out of reach of children and pets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016852\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel 1%: Relief of osteoarthritis pain in joints amenable to topical therapy (eg, ankle, elbow, foot, hand, knee, wrist)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel 3%: Treatment of actinic keratosis (AK) in conjunction with sun avoidance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel 1.16% (Voltaren Emulgel), 2.32% (Voltaren Emulgel Extra Strength) [Canadian products]: Relief of pain associated with acute, localized joint/muscle injuries (eg, sports injuries, strains) in patients &ge;16 years of age (1.16% gel) or &ge;18 years (2.32% gel)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch: Treatment of acute pain due to minor strains, sprains, and contusions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution: Treatment of osteoarthritis pain of the knee</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016846\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diclofenac may be confused with Diflucan</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Voltaren may be confused with traMADol, Ultram, Verelan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch (Flector) contains conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diclofenac may be confused with Duphalac brand name for lactulose [multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flexin: Brand name for diclofenac [Argentina], but also the brand name for cyclobenzaprine [Chile] and orphenadrine [Israel]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flexin [Argentina] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and perfloxacin [Philippines]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016914\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Topical gel:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pruritus (&le;52%), application site rash (35% to 46%), contact dermatitis (2% to 33%), xeroderma (3% to 27%), application site pain (15% to 26%), desquamation (application site 6% to 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum transaminases (&lt;3 x ULN: 15%; &gt;3 x ULN: 2% to 4%; &gt;8 x ULN: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Cardiovascular: Chest pain (1% to 2%), hypertension (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Central nervous system: Headache (7%), hyperesthesia (3%), paresthesia (2%), pain (1% to 2%), migraine (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Dermatologic: Application site paresthesia (&le;8%), vesiculobullous dermatitis (application site 4%), skin rash (4%), alopecia (application site 2%), skin photosensitivity (application site 3%), dermal ulcer (1% to 2%), acne vulgaris (application site 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Endocrine &amp; metabolic: Application site edema (3% to 4%), hypercholesterolemia (1%), hyperglycemia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Gastrointestinal: Diarrhea (2%), dyspepsia (2%), abdominal pain (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Genitourinary: Hematuria (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Hepatic: Increased serum ALT (2% to 4%), increased serum AST (2% to 4%), increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Neuromuscular and skeletal: Back pain (4%), increased creatine phosphokinase (4%), myalgia (2% to 3%), arthralgia (2%), arthropathy (2%), hypokinesia (2%), neck pain (2%), weakness (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Ophthalmic: Conjunctivitis (2% to 4%), eye pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Respiratory: Flu-like symptoms (10%), asthma (2%), dyspnea (2%), pneumonia (2%), sinusitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Miscellaneous: Accidental injury (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Application site irritation, application site reaction (skin carcinoma, hypertonia, skin hypertrophy lacrimation disorder, maculopapular rash, purpuric rash, vasodilation), edema, hepatic failure, hepatic necrosis, hepatitis (fulfillment; with and without jaundice), hepatotoxicity, jaundice, papule (application site), paresthesia, seborrhea, skin blister (application site), skin hypertrophy, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Topical solution:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">&gt;10%: Dermatologic: Xeroderma (application site 22% to 32%; nonapplication site 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Contact dermatitis (2% to 9%), desquamation (application site 7%), application site erythema (4%), pruritus (application site 2% to 4%; nonapplication site 2%); skin rash (3%), application site pain (2%), application site rash (2%), skin sclerosis (application site: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (8%), abdominal pain (6%), diarrhea (4%), flatulence (4%), nausea (2% to 4%), constipation (3%), halitosis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Sinus congestion (2%), sinusitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Accidental injury, aphthous stomatitis, asthma, back pain, blurred vision, body odor, burning sensation of skin, cardiac disease, cataract, chest pain, crusted skin, decreased appetite, depression, dizziness, drowsiness, dysgeusia, dyspnea, eczema, eye pain, facial edema, gastroenteritis, headache, hypersensitivity reaction, hypertension, increased blood pressure, increased serum creatinine, laryngismus, laryngitis, leg cramps, lethargy, lip edema, myalgia, neck stiffness, ophthalmic signs and symptoms, oral mucosa ulcer, otalgia, palpitations, pharyngeal edema, pharyngitis, rectal hemorrhage, skin discoloration, tongue edema, urticaria, visual disturbance, weakness, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Transdermal patch:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&lt;1%), hypoesthesia (&lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperhidrosis (&lt;4%), localized erythema (&lt;4%), localized vesiculation (&lt;4%), skin discoloration (&lt;4%), xeroderma (local: &lt;4%), dermatitis (2%), hypersensitivity reaction (dermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3%), upper abdominal pain (&lt;3%), constipation (&lt;3%), diarrhea (&lt;3%), gastritis (&lt;3%), vomiting (&lt;3%), xerostomia (&lt;3%), dysgeusia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site atrophy (&lt;4%), local irritation (&lt;4%), localized edema, local pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Hyperkinesia (&lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Cerebrovascular accident, edema, exfoliative dermatitis, fluid retention, myocardial infarction, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016862\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to diclofenac (eg, anaphylactic reaction, serious skin reactions) or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; use in the setting of coronary artery bypass graft (CABG) surgery; use on nonintact or damaged skin, including exudative dermatitis, eczema, infected lesions, burns, or wounds.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for NSAIDs is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pennsaid: Concomitant use with other diclofenac containing products or other NSAIDS; active peptic ulcer; history of recurrent GI ulceration; active GI inflammatory disease; significant hepatic impairment or active hepatic disease; severely impaired or deteriorating renal function (CrCl &lt;30 mL/minute); use in children; pregnancy; breastfeeding; prolonged treatment (&gt;3 months)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Voltaren Emulgel: Concomitant use with other diclofenac-containing products or oral NSAIDS; pregnancy (last trimester)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016912\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactoid reactions: Even in patients without prior exposure, anaphylactoid reactions may occur; patients with &quot;aspirin triad&quot; (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Contraindicated in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy (excluding 3% gel).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular events: <b>[US Boxed Warning]: NSAIDs cause an increased risk of serious (and potentially fatal) adverse cardiovascular thrombotic events, including MI and stroke. Risk may occur early during treatment and may increase with duration of use.</b> Relative risk appears to be similar in those with and without known cardiovascular disease or risk factors for cardiovascular disease; however, absolute incidence of serious cardiovascular thrombotic events (which may occur early during treatment) was higher in patients with known cardiovascular disease or risk factors. New-onset hypertension or exacerbation of hypertension may occur (NSAIDs may also impair response to ACE inhibitors, thiazide diuretics, or loop diuretics); may contribute to cardiovascular events; monitor blood pressure; use with caution in patients with hypertension. May cause sodium and fluid retention, use with caution in patients with edema. Avoid use in patients with heart failure (ACCF/AHA [Yancy, 2013]). Avoid use in patients with recent MI unless benefits outweigh risk of cardiovascular thrombotic events. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal events: <b>[US Boxed Warning]: NSAIDs cause an increased risk of serious gastrointestinal inflammation, ulceration, bleeding, and perforation (may be fatal); elderly patients and patients with history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. These events may occur at any time during therapy and without warning.</b> Avoid use in patients with active GI bleeding. Use caution with a history of GI ulcers, concurrent therapy known to increase the risk of GI bleeding (eg, aspirin, anticoagulants and/or corticosteroids, selective serotonin reuptake inhibitors), advanced hepatic disease, coagulopathy, smoking, use of alcohol, or in elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Transaminase elevations have been observed with oral chronic use; closely monitor patients with any abnormal LFT. Rare (sometimes fatal) severe hepatic reactions (eg, fulminant hepatitis, hepatic necrosis, hepatic failure) have occurred with NSAID use; discontinue immediately if signs or symptoms of hepatic disease develop or if systemic manifestations occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE inhibitors). Monitor potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow, which may cause renal decompensation (usually reversible). Patients with impaired renal function, dehydration, hypovolemia, heart failure, hepatic impairment, those taking diuretics and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Long-term NSAID use may result in renal papillary necrosis and other renal injury/toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin reactions: May cause potentially fatal serious skin adverse events, including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); may occur without warning; discontinue use at first sign of skin rash (or any other hypersensitivity). Do not apply topical products to open skin wounds, infected areas, inflammations, or exfoliative dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Asthma: Contraindicated in patients with aspirin-sensitive asthma (excluding 3% gel); severe and potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Coronary artery bypass graft surgery: <b>[US Boxed Warning]: Use is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</b> Risk of MI and stroke may be increased with use following CABG surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; patients with advanced hepatic disease are at an increased risk of GI bleeding with NSAIDs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Avoid use in advanced renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Elderly patients are at greater risk for serious GI, cardiovascular and/or renal adverse events; use with caution. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Avoid contact with eyes and mucous membranes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzoyl alcohol and derivatives: Some dosage forms may contain benzoyl alcohol; large amounts of benzoyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzoyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gel: Avoid occlusive dressings and/or heat application to treated area.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Patch: Contains conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gel, patch, solution: Combination use with oral NSAIDs is not recommended due to increased risk of adverse reactions (eg, rectal hemorrhage; more frequent abnormal creatinine, urea, hemoglobin); do not use concomitantly unless benefit outweighs risks, and monitor patient with periodic laboratory evaluations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016919\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak), CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016920\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9108&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexibuprofen: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Dexibuprofen. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAIDs).  Avoid the use of diclofenac/misoprostol with other NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbinac: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pelubiprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <b> Exceptions: </b>Choline Magnesium Trisalicylate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of a gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants (Tertiary Amine): May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Diclofenac (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zaltoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017406\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">B (gel 3%) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C (gel 1%, solution, patch) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">D (&ge;30 weeks gestation [gel 1%, patch, solution]) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017407\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Diclofenac crosses the placenta following systemic administration. The amount of diclofenac available systemically following topical application is less in comparison to oral doses. Reversible constriction of the ductus arteriosus<i> in utero</i> has been observed following topical application of diclofenac (Torloni 2006). Because they may cause premature closure of the ductus arteriosus, the manufacturer&rsquo;s labeling notes that the use of NSAIDs late in pregnancy should be avoided; the product labeling for the diclofenac topical patch specifically states use should be avoided starting at 30-weeks gestation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9771880\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if diclofenac can be detected in breast milk following topical application. Due to the potential for serious adverse reactions in the nursing infant, the manufacturers recommend that a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. The manufacturer&rsquo;s labeling for the topical solution specifically notes that use is not recommended in women who are breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11370204\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-top:0em;display:inline\">CBC, liver enzymes (periodically during chronic therapy starting 4 to 8 weeks after initiation), BUN/serum creatinine; potassium; monitor urine output; occult blood loss; blood pressure (baseline and during treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24789059\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity, inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016951\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Gel 3%: 6% to 10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; undergoes first-pass metabolism; forms several metabolites (1 with weak activity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Patch: ~12 hours; Solution 1.5%: 36.7 &plusmn; 20.8 hours (single application)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Patch: 10 to 20 hours; Solution 1.5%: 11 &plusmn; 6.4 hours (single application); Gel 3%: 4.5 &plusmn; 8 hours; Gel 1%: 10 to 14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~65%); feces (~35%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017265\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Diclofenac Sodium External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3% (2500 g): $7,770.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Diclofenac Sodium Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (100 g): $54.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3% (100 g): $1,179.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Voltaren Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (100 g): $64.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Diclo Gel Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (1): $460.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (DST Plus Pak Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (1): $96.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Flector Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.3% (5): $74.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Diclofenac Sodium Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5% (150 mL): $689.77</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Klofensaid II Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5% (150 mL): $1,891.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pennsaid Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (112 g): $2,984.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Therapy Pack</b> (Diclo Gel with Xrylix Sheets External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (1): $4,961.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Therapy Pack</b> (Lexixryl Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5% (1): $4,250.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Therapy Pack</b> (Xrylix Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5% (1): $4,961.96</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961971\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adiflam (ET);</li>\n      <li>Algipatch (LK);</li>\n      <li>Almiral Gel (MY, SG, TW);</li>\n      <li>Arthosure (PK);</li>\n      <li>Berifen Gel (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Bi Su Fu (CN);</li>\n      <li>Bufaflam Emulgel (ID);</li>\n      <li>Canfol (TW);</li>\n      <li>Cataflam (VE);</li>\n      <li>Cataflam Emulgel (BR);</li>\n      <li>Clofec Gel (HK);</li>\n      <li>Clofen Creamagel (KW, SA);</li>\n      <li>Curinflam (AR, HK);</li>\n      <li>Diclac (EE);</li>\n      <li>Dicloren (TW);</li>\n      <li>Dosanac (TH);</li>\n      <li>Fastaid Gel (LK);</li>\n      <li>Fenagel (TH);</li>\n      <li>Flexy Gel (TH);</li>\n      <li>Flogosin D (UY);</li>\n      <li>Galtaren (ID);</li>\n      <li>Get-Go-Plus (PH);</li>\n      <li>Jonac Gel (LK);</li>\n      <li>Locagel (AE, QA);</li>\n      <li>Lofenac (TH);</li>\n      <li>Megatic Emulgel (ID);</li>\n      <li>Myfenax (TH);</li>\n      <li>N-Ke'ev Gel (IL);</li>\n      <li>N-Zen Gel (TH);</li>\n      <li>Nac Gel (IN);</li>\n      <li>Novarin (BD);</li>\n      <li>Novo-Difenac (HK);</li>\n      <li>Olfen (TT);</li>\n      <li>Olfen Gel (MY, SG, UA);</li>\n      <li>Painelief Cool Gel (TH);</li>\n      <li>Panaflex Extra (MY);</li>\n      <li>Panaflex Extra Gel (SG);</li>\n      <li>Panamax Gel (SG);</li>\n      <li>Panamax Patch (SG);</li>\n      <li>Physicare Gel (IL);</li>\n      <li>Rapten Gel (UA);</li>\n      <li>Relaxyl Gel (IN);</li>\n      <li>Remethan Gel (SG, TW);</li>\n      <li>Renvol Emulgel (ID);</li>\n      <li>Solaraze (DE, DK, FI, IE, NO, PT, SE);</li>\n      <li>Solaraze Gel (AU);</li>\n      <li>Swiss Relief (IL);</li>\n      <li>Travmagel (MT);</li>\n      <li>Uniren (SG);</li>\n      <li>Vofenac (TR);</li>\n      <li>Volini (LK);</li>\n      <li>Voltadex Emulgel (ID);</li>\n      <li>Voltareactigo (FR);</li>\n      <li>Voltaren (HR, IS, RO, ZW);</li>\n      <li>Voltaren Emulgel (AR, AU, BE, BH, CH, CL, CO, CY, CZ, DE, DK, EE, EG, FI, ID, JO, KW, LT, LU, LV, MT, MY, NO, NZ, PE, PH, PL, QA, SA, SE, SI, SK, TH, TR, TW, UA, VN);</li>\n      <li>Voltarene Emulgel (FR);</li>\n      <li>Voltarol Emulgel (GB, IE);</li>\n      <li>Voltex Kool (HK);</li>\n      <li>Voltic Emulgel (KW, QA);</li>\n      <li>Voren Gel (PH);</li>\n      <li>Vottaren Emulgel (KR);</li>\n      <li>Voveran Emulgel (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-topical-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>J Am Coll Cardiol</i>. 2008;52(18):1502-1517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-topical-drug-information/abstract-text/19017521/pubmed\" target=\"_blank\" id=\"19017521\">19017521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-topical-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flector (diclofenac epolamine) [prescribing information]. Bristol, TN: King Pharmaceuticals; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-topical-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klofensaid II (diclofenac) [prescribing information]. San Fernando, CA: PureTek Corporation; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. <i>Am J Gastroenterol</i>, 2009;104(2):356-362.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-topical-drug-information/abstract-text/19174782/pubmed\" target=\"_blank\" id=\"19174782\">19174782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morales DR, Lipworth BJ, Guthrie B, et al. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. <i>J Allergy Clin Immunol</i>. 2014;134(1):40-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-topical-drug-information/abstract-text/24388008/pubmed\" target=\"_blank\" id=\"24388008\">24388008</a>]</span><span class=\"doi\">10.1016/j.jaci.2013.10.057</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pennsaid 1.5% (diclofenac sodium) [prescribing information]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pennsaid 2% (diclofenac sodium) [prescribing information]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pennsaid 1.5% (diclofenac sodium) [product monograph]. Montreal, Quebec, Canada: Paladin Labs Inc; October 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solaraze (diclofenac sodium) [prescribing information]. Melville, NY: PharmaDerm; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torloni MR, Cordioli E, Zamith MM, et al. Reversible constriction of the fetal ductus arteriosus after maternal use of topical diclofenac and methyl salicylate. <i>Ultrasound Obstet Gynecol. </i>2006;27(2):227-229.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-topical-drug-information/abstract-text/16355417/pubmed\" target=\"_blank\" id=\"16355417\">16355417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voltaren (diclofenac sodium) [prescribing information]. Malvern, PA: Endo Pharmaceuticals, Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voltaren Emulgel Joint-Pain (diclofenac sodium) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Consumer Healthcare Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voltaren Emulgel (diclofenac sodium) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Consumer Healthcare Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-topical-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9108 Version 247.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8016814\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8016848\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8016849\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8017363\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8017006\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13713274\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8017029\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F24789061\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F24789062\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8017238\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8016851\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F27368393\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F9550525\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8016847\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8017033\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8016852\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8016846\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8016914\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8016862\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8016912\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8016919\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8016920\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8017406\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8017407\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9771880\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F11370204\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F24789059\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8016951\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8017265\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961971\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9108|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=diclofenac-topical-patient-drug-information\" class=\"drug drug_patient\">Diclofenac (topical): Patient drug information \t</a></li></ul></div></div>","javascript":null}